"Teva stifled would-be generic competitors to QVAR because the drug laws do not allow for generic substitution of a given ...
The agency has stepped up its campaign against drugmakers' improper listing of patents in the FDA's Orange Book, which it ...
FTC’s latest action targets more than 300 Orange Book patent listings across 10 different companies, which brings the total to more than 400 patent listings across 14 companies and should send a ...
the FTC highlighted specifically its disputes of so-called “junk patent listings” for “blockbuster” weight loss medications. To date, the FTC’s Orange Book patent disputes have been ...
The FTC oversees consumer protections ... Faust: So with respect to these listings, which some people call "junk patents," it makes total sense when you're looking at something like some part ...
FTC targets Novo's Ozempic, others in crackdown on 300-plus 'junk' patent listings in FDA database Novo Holding’s proposed buyout of Catalent has sparked conversation across the industry about ...
"By filing bogus patent listings, pharma companies block competition and inflate the cost of prescription drugs, forcing Americans to pay sky-high prices for medicines they rely on," said FTC chair ...
In a warning letter sent to several drugmakers, including Ozempic's Denmark-based manufacturer Novo Nordisk, the FTC announced that it plans to challenge so-called "junk patents" that keep the ...
The crackdown, which comes six months after FTC challenged 10 pharma majors in a similar fashion, targets so-called “junk” patents — listings the regulator disputes as improper or inaccurate. The most ...
"By filing bogus patent listings, pharma companies block competition and inflate the cost of prescription drugs, forcing Americans to pay sky-high prices for medicines they rely on," said FTC chair ...